ACE2 and COVID-19: Finally, because the entry of SARS-CoV-2 into the host cell via ACE2 disrupts the renin–angiotensin–aldosterone system (RAAS), creating an imbalance between ACE and ACE2 with an increased inflammatory response, we may speculate that this mechanism may also contribute to the development of hyponatremia in COVID-19 patients [7].